Drugs / ADH300004
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00264472 | Jan 2006 → Jun 2009 | neoplasm | Adherex Technologies, Inc. | Suspended | No outcome recorded Stop: Business |
| Phase 1 | NCT00264446 | — | neoplasm | Adherex Technologies, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00319683 | — | hepatocellular carcinoma | Adherex Technologies, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADH300004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00319683 ↗ |
| Known as | Eniluracil | “ADH300004 (Eniluracil) Administered With 5-Fluorouracil (5-FU)” NCT00264472 ↗ |
| Action | Inhibit | “ADH300004 blocks DPD.” NCT00264446 ↗ |
| Route | Oral | “single oral dose of ADH300004” NCT00264446 ↗ |